ArticleLancet regional health. Americas2026

Economic evaluation of dapagliflozin added to standard therapy in chronic heart failure in Argentina: a cost-utility analysis.

Javier Santiago Araujo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.